Setting the Bar for Therapeutic Trials in Non–Small-Cell Lung Cancer: How Low Can We Go?
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Setting the Bar for Therapeutic Trials in Non–Small-Cell Lung Cancer: How Low Can We Go?
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 32, Issue 14, Pages 1389-1391
Publisher
American Society of Clinical Oncology (ASCO)
Online
2014-04-01
DOI
10.1200/jco.2014.55.1929
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Shifting Patterns in the Interpretation of Phase III Clinical Trial Outcomes in Advanced Non–Small-Cell Lung Cancer: The Bar Is Dropping
- (2014) Adrian G. Sacher et al. JOURNAL OF CLINICAL ONCOLOGY
- Right Answers, Wrong Questions in Clinical Research
- (2014) R. I. Horwitz et al. Science Translational Medicine
- Overall survival should be the primary endpoint in clinical trials for advanced non-small cell lung cancer
- (2013) P.K. Cheema et al. Current Oncology
- Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
- (2013) Jyoti D. Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC)
- (2012) Corey J. Langer et al. CANCER TREATMENT REVIEWS
- Progression-Free Survival: Meaningful or Simply Measurable?
- (2012) Christopher M. Booth et al. JOURNAL OF CLINICAL ONCOLOGY
- A Historical Perspective on Clinical Trials Innovation and Leadership
- (2011) David L. DeMets JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Survival Is Not a Good Outcome for Randomized Trials With Effective Subsequent Therapies
- (2011) Marc Buyse et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies
- (2011) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- Adaptive clinical trials in oncology
- (2011) Donald A. Berry Nature Reviews Clinical Oncology
- Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
- (2010) J. C. Soria et al. ANNALS OF ONCOLOGY
- Raising the Bar of Efficacy for Drug Approval Requires an Understanding of Patient Diversity
- (2010) Marc L. Berger et al. JOURNAL OF CLINICAL ONCOLOGY
- Demystify Statistical Significance--Time to Move on From the P Value to Bayesian Analysis
- (2010) J. J. Lee JNCI-Journal of the National Cancer Institute
- When Are "Positive" Clinical Trials in Oncology Truly Positive?
- (2010) A. Ocana et al. JNCI-Journal of the National Cancer Institute
- Time to Progression as a Surrogate Marker for Overall Survival in Patients with Advanced Non-small Cell Lung Cancer
- (2010) Katsuyuki Hotta et al. Journal of Thoracic Oncology
- Incremental Advance or Seismic Shift? The Need to Raise the Bar of Efficacy for Drug Approval
- (2009) Alberto Sobrero et al. JOURNAL OF CLINICAL ONCOLOGY
- How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
- (2009) T. Fojo et al. JNCI-Journal of the National Cancer Institute
- Second-Line Treatment of Advanced Non-small Cell Lung Cancer
- (2008) Cesare Gridelli et al. Journal of Thoracic Oncology
- Endpoints for Assessing Drug Activity in Clinical Trials
- (2008) R. Pazdur ONCOLOGIST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now